SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
NEW OPTIONS AND OPPORTUNITIES IN PrEP
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
PROTECTION AGAINST PENILE OR INTRAVENOUS SHIV CHALLENGES BY BNAB 10-1074 OR 3BNC117 (ABSTRACT
100)
David A Garber
Centers for Disease Control and Prevention, Atlanta, GA, USA
PROTECTION AGAINST VAGINAL SHIV INFECTION WITH AN INSERT CONTAINING TAF AND EVG (ABSTRACT
101)
Charles Dobard
CDC, Atlanta, GA, USA
MODERATE EFFICACY OF ORAL SINGLE-AGENT TAF AGAINST VAGINAL SHIV INFECTION IN MACAQUES (ABSTRACT
102)
Ivana Massud
Centres for Disease Control and Prevention, Atlanta, GA, USA
LYMPHOID TISSUE PHARMACOKINETICS OF TENOFOVIR-ALAFENAMIDE VS -DISOPROXIL FUMARATE (ABSTRACT
103)
Courtney V. Fletcher
University of Nebraska Medical Center, Omaha, NE, USA
THE PHASE 3 DISCOVER STUDY: DAILY F/TAF OR F/TDF FOR HIV PREEXPOSURE PROPHYLAXIS (ABSTRACT
104)
Charles B Hare
Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA
USING EHR DATA TO IDENTIFY POTENTIAL PREP CANDIDATES IN A LARGE HEALTH CARE SYSTEM (ABSTRACT
105)
Julia L. Marcus
Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
PERSISTENCE WITH HIV PREEXPOSURE PROPHYLAXIS IN THE UNITED STATES, 2012-2016 (ABSTRACT
106)
Ya-Lin A Huang
Centers for Disease Control and Prevention, Atlanta, GA, USA
IMPACT OF PREP ON DRUG RESISTANCE AND ACUTE HIV INFECTION, NEW YORK CITY, 2015-2017 (ABSTRACT
107)
Kavita Misra
New York City Department of Health and Mental Hygiene, Long Island City, NY, USA
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
